#Sweden #Lund #Hansa Biopharma #IDEFIRIX #SERB Pharmaceuticals

Hansa Biopharma's Landmark Licensing Agreement with SERB Pharmaceuticals

In an impactful development for the biopharmaceutical industry, Hansa Biopharma AB, a trailblazer in immunomodulatory therapies, has announced a significant exclusive licensing agreement with SERB Pharmaceuticals. This €115 million agreement facilitates the development and commercialization of IDEFIRIX (imlifidase) across the European Union, the United Kingdom, Switzerland, Norway, Liechtenstein, Iceland, and the MENA region.

Understanding IDEFIRIX and Its Importance

IDEFIRIX is a pioneering treatment aimed at addressing the pressing challenges faced by highly sensitized adult kidney transplant patients. It works by targeting and cleaving immunoglobulin G (IgG) antibodies within a rapid timeframe of 2 to 6 hours, thereby enhancing the chances of successful transplantation. The European Commission has conditionally authorized IDEFIRIX specifically for patients who have a positive crossmatch test against a deceased donor, marking a groundbreaking solution in the realm of transplantation for a group long considered to have limited options.

Transformative Impact for Hansa

Renée Aguiar-Lucander, CEO of Hansa Biopharma, described the agreement as transformative, highlighting its potential to enhance the company’s financial position and solidify a pathway to profitability pending U.S. approval. Serb's established commercial infrastructure and track record in rare diseases will enable both companies to maximize the reach and impact of IDEFIRIX in regions where the need is critical.

Aguiar-Lucander stated, "This agreement allows patients in the region access to a partner with a proven track record. It not only crystallizes the value of our franchise but significantly strengthens our financial standing, ensuring that we are positioned for a successful U.S. launch, subject to approval in 2026."

A Commitment to Access and Innovation

Jeremie Urbain, Chairman of SERB, emphasized the company’s dedication to expanding transplantation access for highly sensitized patients. SERB’s strategic focus on rare and urgent medical conditions aligns perfectly with the innovative nature of IDEFIRIX, allowing for an extensive reach across Europe and MENA.

SERB brings over 25 years of experience in the pharmaceutical sector, particularly in rare diseases and emergencies. With a strong portfolio that includes more than 70 products, SERB is well-equipped to ensure that IDEFIRIX can reach those in dire need of treatment, capitalizing on its proven capabilities.

Financial and Regulatory Framework

Under the terms of this licensing agreement, Hansa will receive an upfront payment of €110 million, with an additional €5 million due upon the acceptance of the filing for full approval by the European Medicines Agency (EMA). Hansa will actively support SERB throughout the filing and EMA review processes in conjunction with ongoing studies aimed at demonstrating the long-term efficacy of IDEFIRIX.

Hansa remains committed to its robust research and development pipeline, and this partnership will enable it to focus on advancing other innovative therapies alongside commercially leveraging its IgG-cleaving enzyme technology.

The completion of this agreement is contingent upon fulfilling customary conditions, including regulatory approvals, and is anticipated to be finalized within the next 60 days.

Looking Ahead: Conference and Future Plans

To discuss this landmark agreement further, Hansa Biopharma will host a telephone conference on May 19, 2026, where insights will be shared regarding future directions for IDEFIRIX and other developments within the company. This event will provide an opportunity for stakeholders and interested parties to engage with Hansa’s leadership directly.

Conclusion

Hansa Biopharma's partnership with SERB Pharmaceuticals marks a significant milestone in the fight against kidney disease and transplant challenges. With IDEFIRIX as a first-in-class treatment option, patients in Europe and the MENA region can look forward to improved prospects for kidney transplantation, thanks to the collaborative efforts of these innovative companies.

For more information on this partnership and the upcoming conference, stakeholders can refer to Hansa Biopharma's official website.